Stockreport

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF - Amylyx expects early cohort data from LUMINA this year- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the [Read more]